Kory James Wentworth - Sep 2, 2025 Form 4 Insider Report for Entrada Therapeutics, Inc. (TRDA)

Role: Chief Financial Officer
Signature: /s/ Jared Cohen, as Attorney-in-Fact
Stock symbol: TRDA
Transactions as of: Sep 2, 2025
Transactions value $: -$9,416
Form type: 4
Date filed: 9/4/2025, 05:02 PM
Previous filing: Apr 4, 2025
Next filing: Nov 24, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
WENTWORTH KORY JAMES	Chief Financial Officer	C/O ENTRADA THERAPEUTICS, INC., ONE DESIGN CENTER PLACE, SUITE 17-500, BOSTON	/s/ Jared Cohen, as Attorney-in-Fact	2025-09-04	0001725663

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TRDA	Common Stock	Tax liability	-$9.42K	-1.73K	-1.44%	$5.43	119K	Sep 2, 2025	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.36 to $5.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Content

This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.36 to $5.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.